Loading…
Loading…
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
Launched on June 23, 2005, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Bank of America Corp DE raised its stake in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 234.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,458 shares of the company's stock after purchasing an additional 52,165 shares during the quarter.
Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of just over 30 pharmaceutical stocks, while FHLC diversifies across more than 300 holdings.
The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excluding Japan was little changed after swinging between gains and losses.
Launched on 06/23/2005, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.